Pennsylvania federal court grants summary judgment to Firm client Novartis in Aredia®/Zometa® personal injury lawsuit.
W.D. Pa. -- United States District Court for the Western District of Pennsylvania
On October 7, 2015, Judge Mark Hornak granted complete summary judgment to firm client Novartis Pharmaceuticals Corporation after plaintiffs failed to satisfy their proximate cause burden in a failure-to-warn lawsuit alleging that the prescription drugs Aredia® and Zometa® caused osteonecrosis of the jaw (“ONJ”). Bock v. Novartis Pharm. Corp., No. 2:10-cv-1338-MRH (W.D. Pa. Oct. 7, 2015).
Based on the deposition testimony of the oncologists who prescribed these Novartis drugs to Mr. Bock, Judge Hornak concluded that “both physicians indicated that they would still prescribe the drug today if presented with a patient such as Bock because, in their medical judgment, the benefits of the drug significantly outweigh the risks.” Id. at 14-15. Judge Hornak also pointed out that Mr. Bock “consented to each of the unavoidable dental procedures that ultimately precipitated his ONJ despite being thoroughly warned as to the potential risks.” Id. at 15. Judge Hornak rejected plaintiffs’ argument that a summary judgment decision should be deferred until they have presented expert testimony regarding what information should have been provided in the Aredia®/Zometa® warning labels. Id. (“the issue raised in the instant motion is proximate cause, rather than the adequacy of the warnings”). He also rejected plaintiffs’ contention that the oncologists’ testimony lacked credibility and must be evaluated by a jury. Id. at 17 (explaining that plaintiffs have “not pointed to any evidence in the record that might contradict each physician’s testimony” and that “a plaintiff cannot survive a well-supported summary judgment motion by simply asserting that the opposing witnesses lack credibility”).